IDEAYA Biosciences (IDYA) Non-Current Deffered Revenue (2018 - 2025)

IDEAYA Biosciences has reported Non-Current Deffered Revenue for 5 years, with the latest figure at $1.7 million in Q3 2025.

• Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $1.7 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $1.7 million (changed N/A YoY) and the FY2022 annual result came in at $5.2 million, down 83.38% from the prior year.
• Non-Current Deffered Revenue declined to $1.7 million in Q3 2025 per IDYA's latest filing, from $5.2 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $52.1 million in Q1 2021 and troughed at $1.7 million in Q3 2025.
• A 3-year average of $22.5 million and a median of $10.2 million in 2022 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2021 and 2022: Non-Current Deffered Revenue dropped 15.02% in 2021, then sank 83.38% in 2022.
• Over 3 years, Non-Current Deffered Revenue stood at $31.2 million in 2021, then tumbled by 83.38% to $5.2 million in 2022, then slumped by 67.68% to $1.7 million in 2025.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $1.7 million, $5.2 million, and $7.3 million for Q3 2025, Q4 2022, and Q3 2022 respectively.